Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.
Hum Vaccin Immunother. 2021 Oct 3;17(10):3729-3734. doi: 10.1080/21645515.2021.1928461. Epub 2021 Jun 7.
: The purpose of this paper was to analyze the prevalence of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core anti-body (anti-HBc)in1-29 years old living in the most populous eastern province of China,22 years after introduction of hepatitis B vaccine (HepB) vaccination of infants and provide provincial baseline data for developping a better prevention and control plan for hepatitis B virus (HBV)in Jiangsu Province, China: The incidence rates of HBV in Jiangsu province from 2004 to 2014 were obtained from the National Notifiable Disease Reporting System (NNDRS). A stratified cluster random sampling method was used to select 3,002 participants aged 1-29 years across 13 HBV monitoring points throughout the province, which had been classified as either urban or rural. HBV serological markers were measured by Abbott microparticle enzyme immunoassay (MEIA) kits (Abbott Laboratories, Chicago, Illinois).: The incidence of hepatitis B decreased by approximately 71.44% in Jiangsu province between 2004 and 2014. Serological assessments showed that the prevalence of the HBsAg, anti-HBc, and anti-HBsin the 1-29 age group were 1.20%, 5.33%,and 66.89%, respectively. There was a significantly lower prevalence of HepB who were vaccinated than in unvaccinated subjects (0.46% vs 14.93%, < .0001). Among these the ages of 1-29, the coverage rate drops from 97.7% to 56.6% with age,andthe timely rate among people aged 1-14 years was 90.93%.: Since the HepB was integrated into the immunization programme in Jiangsu province,the rate of hepatitis B reported and the prevalence of HBsAg decreased significantly, and the coverage of HepB and the vaccination rate within 24 hours after birth have played an important role in reducing HBV infection.
本研究旨在分析中国东部人口最多的省份江苏省 1 至 29 岁人群乙型肝炎表面抗原(HBsAg)、乙型肝炎表面抗体(抗-HBs)和乙型肝炎核心抗体(抗-HBc)的流行情况,这是乙型肝炎疫苗(HepB)接种婴儿 22 年后的结果,为江苏省制定更好的乙型肝炎病毒(HBV)预防和控制计划提供省级基线数据:从国家法定传染病报告系统(NNDRS)获得 2004 年至 2014 年江苏省 HBV 发病率数据。采用分层整群随机抽样方法,在全省 13 个 HBV 监测点选取 3002 名 1 至 29 岁的参与者,分为城市和农村。使用 Abbott 微粒子酶免疫分析法(MEIA)试剂盒(Abbott Laboratories,芝加哥,伊利诺伊州)检测 HBV 血清学标志物。2004 年至 2014 年期间,江苏省 HBV 发病率下降了约 71.44%。血清学评估显示,1-29 岁年龄组 HBsAg、抗-HBc 和抗-HBs 的流行率分别为 1.20%、5.33%和 66.89%。与未接种人群相比,接种 HepB 的人群 HBsAg 患病率明显较低(0.46% vs 14.93%, < 0.0001)。在 1-29 岁年龄组中,随着年龄的增长,疫苗接种覆盖率从 97.7%降至 56.6%,1-14 岁人群的及时接种率为 90.93%。自江苏省将 HepB 纳入免疫规划以来,乙型肝炎报告发病率和 HBsAg 流行率显著下降,HepB 覆盖率和出生后 24 小时内的接种率在降低 HBV 感染方面发挥了重要作用。